Polyclonal B cell activation is a hallmark of the immune dysregulation in New Zealand Black (NZB) mice. We have previously shown that the splenic B cell activation is associated with increased CD80 expression. Here we show that abnormal expansions of CD80-expressing GC, CD5(+), marginal zone (MZ) precursor and MZ B cells produce this increase. To investigate the role of BCR engagement in the generation and activation of these populations, a non-self-reactive Ig Tg was introduced onto the NZB background. NZB Ig-Tg mice lacked Tg CD5(+) and peanut agglutinin(+) B cells, confirming the role of endogenous Ag in their selection. Although the increased proportion of MZ B cells was retained in NZB Ig-Tg mice, CD80 expression on these cells was reduced as compared to non-Tg NZB mice, suggesting a role for BCR engagement with endogenous Ag in their activation. Examination of CD40L-knockout NZB mice showed no difference in the abnormal activation or selection of the B cell populations, with the exception of GC cells, as compared to wild-type NZB mice. Thus, polyclonal B cell activation in NZB mice does not require CD40 engagement, but results, in part, from dysregulated BCR-specific mechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.200737334DOI Listing

Publication Analysis

Top Keywords

nzb mice
20
cell activation
12
zealand black
8
mice
8
mice polyclonal
8
polyclonal cell
8
nzb
8
cd80 expression
8
role bcr
8
bcr engagement
8

Similar Publications

Article Synopsis
  • * In studies using a mouse model lacking the NPC1 protein in immune cells, researchers found significant changes in microglial lipid profiles, increased microglial activity, and symptoms resembling NPC disease, such as lifespan reduction and motor issues.
  • * Monitoring translocator protein (TSPO) levels in the blood may be useful for assessing NPC disease progression and treatment response, as shown by changes in TSPO levels following a specific therapy that appeared beneficial for patients.
View Article and Find Full Text PDF

Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.

Arthritis Res Ther

November 2024

GenNBio Inc, 80, Deurimsandan 2-ro, Cheongbuk-eup, Pyeongtaek-si, Gyeonggi-do, 17796, Republic of Korea.

Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic, incurable autoimmune disease, prompting the need for effective treatments, such as using extracellular vesicles (EV) from mesenchymal stem cells (iMSCs) primed with immune cell media.
  • In the study, female NZB/W F1 mice were divided into three groups to assess the effects of CM-EV and ASC-EV treatments compared to a control group, with assessment done over 36 weeks.
  • Results showed that CM-EV treatment enhanced survival rates, reduced harmful antibodies, and improved kidney health, while both EV types decreased pro-inflammatory macrophages, indicating their potential in modulating SLE’s immune response.
View Article and Find Full Text PDF

Neuropilin-1 as a Key Molecule for Renal Recovery in Lupus Nephritis: Insights from an NZB/W F1 Mouse Model.

Int J Mol Sci

October 2024

Rheumatology Research Group-Lupus Unit, Vall d'Hebrón University Hospital, Vall d'Hebrón Research Institute (VHIR), Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.

Article Synopsis
  • - Systemic lupus erythematosus (SLE) is an autoimmune disease affecting many organs, with lupus nephritis (LN) impacting 40-50% of patients and potentially leading to serious kidney complications like end-stage renal disease (ESRD).
  • - This study investigates the role of neuropilin-1 (NRP-1), a receptor in kidney tissue, as a biomarker for kidney recovery in LN using a mouse model, demonstrating a significant increase in NRP-1 levels over time.
  • - High urinary NRP-1 levels (above 34.40 ng/mL) were strongly associated with positive renal outcomes, highlighting NRP-1's potential as a reliable biomarker for kidney recovery in
View Article and Find Full Text PDF
Article Synopsis
  • Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organs, with kidney issues (lupus nephritis) being a serious complication and a leading cause of death in affected patients.
  • Current mouse models used to study SLE/LN show diverse immune responses that may not fully reflect human disease, highlighting the need for better models that parallel human pathways for developing new treatments.
  • The research compared the immune responses of five different mouse models of SLE/LN to human data, finding differences in cell types and responses, which could help in understanding the disease and improving therapy translation for patients.
View Article and Find Full Text PDF
Article Synopsis
  • CD44 is a glycoprotein linked to kidney inflammation and fibrosis, specifically studied in a mouse model for lupus nephritis (LN) and in human patients with active LN.
  • The research showed that CD44 was absent in healthy kidneys but expressed in kidney cells of LN patients, and treatment with anti-CD44 antibodies improved kidney health in mice by reducing immune cell infiltration and fibrosis markers.
  • Serum CD44 levels increased before clinical symptoms of renal flare in patients, effectively distinguishing those with active LN from healthy individuals and other kidney-related conditions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!